Evidence map›Paper›PMID 36336932›Full record

ReviewJournal of Alzheimer's disease : JAD2023

A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.

Li Huang, Zhaogang Lu, Hexin Zhang, Hongyong Wen, Zongji Li, Qibing Liu, Rui Wang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Alzheimer's disease : JAD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Li HuangSchool of Pharmacy, Ningxia Medical University, Yinchuan, China.
Zhaogang LuDepartment of Pharmacy, People's Hospital of Ningxia /First Affiliated Hospital of Northwest University for Nationalities, Yinchuan, China.
Hexin ZhangSchool of Pharmacy, Ningxia Medical University, Yinchuan, China.
Hongyong WenSchool of Pharmacy, Ningxia Medical University, Yinchuan, China.
Zongji LiLaboratory Department, Clinical College of Ningxia Medical University, Yinchuan, China.
Qibing LiuDepartment of Pharmacology, Hainan Medical University, Haikou, China.
Rui WangSchool of Pharmacy, Ningxia Medical University, Yinchuan, China.
Ningxia Medical University · CNHainan Medical University · CNNorthwest Minzu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases worldwide. The accumulation of amyloid-β (Aβ) protein and plaque formation in the brain are two major causes of AD. Interestingly, growing evidence demonstrates that the gut flora can alleviate AD by affecting amyloid production and metabolism. However, the underlying mechanism remains largely unknown. This review will discuss the possible association between the gut flora and Aβ in an attempt to provide novel therapeutic directions for AD treatment based on the regulatory effect of Aβ on the gut flora.

Indexed as

Alzheimer DiseaseGastrointestinal MicrobiomeAmyloid beta-PeptidesAmyloidogenic ProteinsBrainHumansAmyloid beta-PeptidesAmyloidogenic ProteinsAlzheimer’s diseaseamyloid-βcolitisinsulin resistanceintestinal floraneuroinflammation

Identifiers

PMID36336932
PMCPMC10473151
OpenAlexW4308009643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.